课题基金 / 基金详情

HHSN2612012000201/HHSN26100006 Title: Preclinical In Vitro And In Vivo Screening Assays For Cancer Preventative Reagent Development, Project: Targeting CCK2R for Pancreatic Cancer Prevention

HHSN2612012000201/HHSN26100006 Title: Preclinical In Vitro And In Vivo Screening Assays For Cancer Preventative Reagent Development, Project: Targeting CCK2R for Pancreatic Cancer Prevention
HHSN2612012000201/HHSN26100006 标题：癌症预防试剂开发的临床前体外和体内筛选测定，项目：靶向 CCK2R 预防胰腺癌
批准号：
8944735
负责人：
CHINTHALAPALLY RAO
金额：
$47.46万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
项目状态：
已结题
起止时间：
2014-08-26 至 2016-08-25
来源：
https://reporter.nih.gov/project-details/8944735
关键词：
Animal ModelBiological AssayBiological MarkersBreedingClinical ResearchContractorContractsDevelopmentDoseGene Expression ProfileIn VitroMalignant NeoplasmsMalignant neoplasm of pancreasMaximum Tolerated DoseMediatingMessenger RNAMicroRNAsMusPathway interactionsPharmacodynamicsPhasePositron-Emission TomographyPre-Clinical ModelReagentSignal TransductionToxic effectTransgenic MiceTreatment Protocolscancer chemopreventioncancer preventiondesignin vivomouse modelpancreatic neoplasmpre-clinicalresponsescreeningtumor growth

项目摘要

项目成果

CHINTHALAPALLY RAO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The contract is to evaluate two selective CCR2R antagonists, (YF476 and JNJ-26070109) for pancreatic cancer prevention in preclinical models. Specifically, the Contractor shall establish the optimal dose and maximal tolerated dose (MTD) of these two antagonists in mice and then assess the pancreatic cancer prevention efficacy in p48Cre/+-LSL-KrasG12D/+ transgenic mouse model of pancreatic cancer. In addition, the Contractor shall explore critical biomarkers of pharmacodynamic efficacy, which will be applicable to early-phase clinical studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERSTASK ORDER TITLE: PREVENTING FAP-CRC USING
海外基金